Summary
Edwards Lifesciences Corporation's 2014 10-K filing highlights strong revenue growth, driven significantly by its Transcatheter Heart Valve Therapy (THVT) segment, which saw a substantial increase of 33.3% year-over-year. This growth was propelled by the successful commercial launches of the Edwards SAPIEN XT in the U.S. and the SAPIEN 3 in Europe. The company also reported a significant increase in net income, largely due to an upfront payment received from Medtronic related to a patent litigation settlement. The Surgical Heart Valve Therapy segment demonstrated steady growth, while the Critical Care segment experienced a modest increase in sales. Financially, the company ended 2014 with robust cash reserves and manageable debt levels. Research and development spending remained a priority, underscoring the company's commitment to innovation in structural heart disease and critical care monitoring. Despite the positive financial performance, the company faces ongoing risks related to competition, regulatory scrutiny, and the complex international healthcare environment. Investors should note the company's continued investment in R&D, its strategic product pipeline, and the significant impact of the Medtronic litigation settlement on its 2014 results.
Financial Highlights
53 data points| Revenue | $2.32B |
| Cost of Revenue | $625.60M |
| Gross Profit | $1.70B |
| R&D Expenses | $346.50M |
| SG&A Expenses | $858.00M |
| Interest Expense | $17.20M |
| Net Income | $811.10M |
| EPS (Basic) | $1.27 |
| EPS (Diluted) | $1.25 |
| Shares Outstanding (Basic) | 639.00M |
| Shares Outstanding (Diluted) | 651.00M |
Key Highlights
- 1Transcatheter Heart Valve Therapy (THVT) sales surged by 33.3% to $943.6 million, driven by the launch of SAPIEN XT in the U.S. and SAPIEN 3 in Europe.
- 2Net income significantly increased by 108.5% to $811.1 million, boosted by a $750 million upfront payment from Medtronic for patent litigation settlement.
- 3Total net sales grew 13.6% to $2.32 billion, with international sales accounting for 55% of the total.
- 4Surgical Heart Valve Therapy sales increased by 3.1% to $826.1 million.
- 5Research and development expenses increased by 7.3% to $346.5 million, representing 14.9% of net sales.
- 6The company ended the year with $653.8 million in cash and cash equivalents and $785.0 million in short-term investments.
- 7Edwards Lifesciences announced a new $750 million stock repurchase program.